Synthetic Strategies for Improving Solubility: Optimization of Novel Pyrazolo[1,5‑a]pyrimidine CFTR Activator That Ameliorates Dry Eye Disease

Dry eye disease (DED) is one of the most prevalent ocular diseases but has limited treatment options. Cystic fibrosis transmembrane conductance regulator (CFTR), a major chloride channel that stimulates fluid secretion in the ocular surface, may pave the way for new therapeutic strategies for DED. H...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 66; no. 1; pp. 413 - 434
Main Authors Kim, Bo Yi, Oh, Changmok, Jeon, Dongkyu, Jun, Ikhyun, Lee, Ho K., Kim, Bo-Rahm, Park, Jinhong, Seo, Kyoung Yul, Kim, Kyeong-A, Lim, Dami, Lee, Seolhee, Lee, Jooyun, Yoon, Hongchul, Kim, Tae-im, Namkung, Wan
Format Journal Article
LanguageEnglish
Published WASHINGTON American Chemical Society 12.01.2023
Amer Chemical Soc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Dry eye disease (DED) is one of the most prevalent ocular diseases but has limited treatment options. Cystic fibrosis transmembrane conductance regulator (CFTR), a major chloride channel that stimulates fluid secretion in the ocular surface, may pave the way for new therapeutic strategies for DED. Herein, we report the optimization of Cact-3, a potent CFTR activator with poor solubility, to 16d, a potent CFTR activator with suitable solubility for eye drop formulation. Notably, 16d was well distributed in target tissues including cornea and conjunctiva with minimal systemic exposure in rabbit. Topical ocular instillation of 16d significantly enhanced tear secretion and improved corneal erosion in a mouse model of DED. In addition, 16d significantly reduced mRNA expression of pro-inflammatory cytokines including IL-1β, IL-17, and TNF-α and MMP2 in cornea and conjunctiva of DED mice.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-2623
1520-4804
DOI:10.1021/acs.jmedchem.2c01382